FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a stable pharmaceutical preparation comprising (i) 0.1–100 mg/ml of a human antibody which specifically binds to human nerve growth factor (hNGF), wherein the antibody comprises a pair of amino acid sequences of a heavy chain variable region and a light chain variable region (HCVR/LCVR), selected from a group consisting of (i) SEQ ID NO: 20/22 and (ii) SEQ ID NO: 4/12, (ii) 0.01–1.0 % polysorbate 20, (iii) 1–20 % saccharose and (iv) 1–50 mM acetate.
EFFECT: invention provides stability of the preparation stored for six months or more at 5 °C.
11 cl, 12 ex, 38 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES TO C5 | 2018 |
|
RU2787595C2 |
| STABLE AQUEOUS COMPOSITIONS BASED ON ANTIBODIES | 2014 |
|
RU2763787C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
